The Board of Directors of the company inter alia, considered and approved the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2025 today in its ....
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 2.5 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JHS Svendgaard Laboratories reported audited financial results for FY2026 with revenue from operations growing 10.5% to Rs 10,169.47 lakhs from Rs 9,199.73 lakhs in FY2025. The company reduced its net loss significantly from Rs 1,973.84 lakhs to Rs 191.73 lakhs year-on-year, showing operational improvement. The auditor issued an unmodified (clean) opinion on the financial statements. However, the auditors flagged material weaknesses in internal controls related to trade receivables/payables monitoring, ERP reporting limitations, and inventory management. An emphasis of matter was raised on capital advances of Rs 4,190.82 lakhs (Rs 2,862.52 lakhs for HP manufacturing facilities and Rs 1,328.30 lakhs for J&K project) which management considers recoverable. Q4 FY26 showed a profit of Rs 78.92 lakhs compared to a loss of Rs 618.86 lakhs in Q4 FY25.
The substantial reduction in losses is a positive sign for shareholders, though the company remains in loss territory. The clean audit opinion provides comfort on financial reporting integrity, but the material weaknesses in internal controls noted by auditors could raise concerns for investors regarding operational efficiency and risk management.